EUS-FNA Biopsies to Guide Precision Medicine in Pancreatic Cancer: Results of a Pilot Study to Identify
KRAS
endoscopic ultrasound
molecular analysis
pancreatic cancer
precision medicine
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
03
09
2021
accepted:
18
11
2021
entrez:
27
12
2021
pubmed:
28
12
2021
medline:
28
12
2021
Statut:
epublish
Résumé
Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer death and lacks effective treatment options. Diagnostic endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) biopsies represent an appealing source of material for molecular analysis to inform targeted therapy, as they are often the only available tissue for patients presenting with PDAC irrespective of disease stage. However, EUS-FNA biopsies are typically not used to screen for precision medicine studies due to concerns about low tissue yield and quality. Epidermal growth factor receptor (EGFR) inhibition has shown promise in clinical trials of unselected patients with advanced pancreatic cancer, but has not been prospectively tested in Fresh frozen EUS-FNA or surgical biopsies from PDAC patient tumours were used to screen for 275 patient biopsies were screened for This study demonstrates proof-of-principle feasibility to molecularly screen patients with pancreatic cancer for targeted therapies, and confirms diagnostic EUS-FNA biopsies as a reliable source of tumour material for molecular analysis. Single agent panitumumab was safe and tolerable but led to no objective tumour responses in this population.
Sections du résumé
BACKGROUND
BACKGROUND
Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer death and lacks effective treatment options. Diagnostic endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) biopsies represent an appealing source of material for molecular analysis to inform targeted therapy, as they are often the only available tissue for patients presenting with PDAC irrespective of disease stage. However, EUS-FNA biopsies are typically not used to screen for precision medicine studies due to concerns about low tissue yield and quality. Epidermal growth factor receptor (EGFR) inhibition has shown promise in clinical trials of unselected patients with advanced pancreatic cancer, but has not been prospectively tested in
PATIENTS AND METHODS
METHODS
Fresh frozen EUS-FNA or surgical biopsies from PDAC patient tumours were used to screen for
RESULTS
RESULTS
275 patient biopsies were screened for
CONCLUSIONS
CONCLUSIONS
This study demonstrates proof-of-principle feasibility to molecularly screen patients with pancreatic cancer for targeted therapies, and confirms diagnostic EUS-FNA biopsies as a reliable source of tumour material for molecular analysis. Single agent panitumumab was safe and tolerable but led to no objective tumour responses in this population.
Identifiants
pubmed: 34956889
doi: 10.3389/fonc.2021.770022
pmc: PMC8696205
doi:
Types de publication
Journal Article
Langues
eng
Pagination
770022Informations de copyright
Copyright © 2021 Lundy, Harris, Zalcberg, Zimet, Goldstein, Gebski, Borsaru, Desmond, Swan, Jenkins and Croagh.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. This study received partial funding from Amgen. The funder had the following involvement with the study: review of study design, provision of study drug and partial funding for study procedures. The handling editor SS and the reviewer EC have declared a shared parent affiliation with the author VG at the time of review.
Références
Expert Rev Med Devices. 2018 Feb;15(2):127-135
pubmed: 29334842
Surgery. 1996 Oct;120(4):680-5; discussion 686-7
pubmed: 8862378
Oncologist. 2019 May;24(5):589-e160
pubmed: 30679315
Mol Cancer Ther. 2002 Aug;1(10):777-83
pubmed: 12492110
Eur J Cancer. 2014 Aug;50(12):2072-81
pubmed: 24915778
Mol Cancer Ther. 2011 Oct;10(10):1993-9
pubmed: 21862683
J Clin Oncol. 2010 Nov 1;28(31):4697-705
pubmed: 20921465
Science. 2008 Sep 26;321(5897):1801-6
pubmed: 18772397
Cancer Lett. 2021 Jan 28;497:221-228
pubmed: 33127389
Pancreas. 2019 Nov/Dec;48(10):1274-1284
pubmed: 31688590
World J Surg Oncol. 2016 May 16;14:146
pubmed: 27183870
Clin Cancer Res. 2021 Nov 1;27(21):5900-5911
pubmed: 34400416
Drug Des Devel Ther. 2016 Jun 13;10:1961-72
pubmed: 27358556
Cold Spring Harb Mol Case Stud. 2019 Dec 13;5(6):
pubmed: 31519698
BMC Cancer. 2020 Jul 8;20(1):633
pubmed: 32641104
Br J Cancer. 2015 Sep 29;113(7):989-95
pubmed: 26372701
J Exp Clin Cancer Res. 2018 Jul 9;37(1):140
pubmed: 29986755
J Clin Oncol. 2016 Nov 10;34(32):3914-3920
pubmed: 27621395
Clin Cancer Res. 2018 Oct 15;24(20):5018-5027
pubmed: 29954777
Clin Cancer Res. 2015 May 1;21(9):2029-37
pubmed: 25896973
Endosc Ultrasound. 2018 Jul-Aug;7(4):263-269
pubmed: 28836511
Ann Oncol. 2017 Oct 1;28(10):2429-2435
pubmed: 28961832
J Clin Oncol. 2008 Apr 1;26(10):1626-34
pubmed: 18316791
J Clin Oncol. 2007 May 20;25(15):1960-6
pubmed: 17452677
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Endoscopy. 2017 Oct;49(10):989-1006
pubmed: 28898917
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Invest New Drugs. 2005 Oct;23(5):485-7
pubmed: 16133800
J Natl Cancer Inst. 2013 Oct 2;105(19):1441-56
pubmed: 24052618
Nature. 2015 Feb 26;518(7540):495-501
pubmed: 25719666
Nat Commun. 2015 Apr 09;6:6744
pubmed: 25855536
Cancer. 2010 Dec 15;116(24):5599-607
pubmed: 20824720
Clin Cancer Res. 2019 Sep 1;25(17):5376-5387
pubmed: 31175091
J Natl Compr Canc Netw. 2020 Apr;18(4):380-391
pubmed: 32259785
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Gut. 2021 Jan;70(1):148-156
pubmed: 32350089
Br J Cancer. 2013 Feb 5;108(2):469-76
pubmed: 23169292
Oncology. 2020;98(1):53-60
pubmed: 31578019
Lancet. 2016 Feb 6;387(10018):545-557
pubmed: 26615328
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Ann Oncol. 2015 Sep;26 Suppl 5:v56-68
pubmed: 26314780
Clin Cancer Res. 2018 Mar 15;24(6):1344-1354
pubmed: 29288237
J Gastrointest Oncol. 2018 Feb;9(1):1-10
pubmed: 29564165
United European Gastroenterol J. 2020 Jun;8(5):594-606
pubmed: 32213029
Cell. 1988 May 20;53(4):549-54
pubmed: 2453289
J Exp Clin Cancer Res. 2020 Oct 28;39(1):227
pubmed: 33115526
J Clin Oncol. 2011 May 20;29(15):2011-9
pubmed: 21502544
J Clin Med. 2019 May 29;8(6):
pubmed: 31146420
Cancer Discov. 2018 Sep;8(9):1112-1129
pubmed: 29853643
Eur J Cancer. 2011 Jul;47(11):1676-81
pubmed: 21565490
N Engl J Med. 2019 Jul 25;381(4):317-327
pubmed: 31157963
Gastrointest Endosc. 2013 Oct;78(4):596-608
pubmed: 23660563
Am J Pathol. 1998 Jun;152(6):1501-7
pubmed: 9626054
World J Gastrointest Endosc. 2018 Oct 16;10(10):267-273
pubmed: 30364716
J Clin Oncol. 2013 Sep 20;31(27):3432-8
pubmed: 23960185
Cancer Res. 2000 Jun 1;60(11):2926-35
pubmed: 10850439
J Clin Med. 2019 Aug 05;8(8):
pubmed: 31387310
Endoscopy. 2016 Apr;48(4):339-49
pubmed: 26561917
United European Gastroenterol J. 2015 Aug;3(4):343-52
pubmed: 26279842
Nature. 2012 Nov 15;491(7424):399-405
pubmed: 23103869
Biochem Biophys Res Commun. 2007 Jul 6;358(3):698-703
pubmed: 17512909
Oncology. 2011;81(1):3-8
pubmed: 21894049
BMC Med. 2018 Aug 21;16(1):125
pubmed: 30126408
Gastroenterology. 2019 Jun;156(8):2242-2253.e4
pubmed: 30836094
Int J Cancer. 2017 May 15;140(10):2331-2343
pubmed: 28198009
Semin Cancer Biol. 2019 Feb;54:91-100
pubmed: 29409706
GE Port J Gastroenterol. 2021 Apr;28(3):185-192
pubmed: 34056041
J Clin Oncol. 2020 Aug 5;:JCO2001364
pubmed: 32755482
Eur J Cancer. 2019 Feb;108:78-87
pubmed: 30654298
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140